What does Neurizon Therapeutics do?

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company based in Melbourne, Australia. The company is dedicated to developing therapeutics for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s, Parkinson’s, and Huntington’s. Originally founded in 2000 as PharmAust Limited, it rebranded to Neurizon Therapeutics in October 2024 to highlight its focus on patient-centered treatments. Neurizon's lead product, NUZ-001 (S-Monepantel or MPL), is a small molecule mTOR inhibitor designed to activate autophagy in neuronal cells. The company is advancing its clinical trials, including Phase II trials for ALS, with participation in the HEALEY ALS Platform Trial at Massachusetts General Hospital. Neurizon has achieved positive results in earlier trials, demonstrating safety and efficacy in ALS patients. The company is also exploring broader applications for NUZ-001 in other neurodegenerative conditions and has received Orphan Medicinal Product Designation from the EMA for ALS, ensuring market exclusivity for ten years.